Tabula Rasa HealthCare Inc (NASDAQ:TRHC) President Orsula V. Knowlton sold 8,000 shares of Tabula Rasa HealthCare stock in a transaction that occurred on Friday, May 17th. The shares were sold at an average price of $47.11, for a total transaction of $376,880.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link.
TRHC stock opened at $45.35 on Wednesday. The company has a debt-to-equity ratio of 1.31, a current ratio of 1.80 and a quick ratio of 1.73. Tabula Rasa HealthCare Inc has a fifty-two week low of $40.86 and a fifty-two week high of $91.16. The company has a market capitalization of $964.41 million, a P/E ratio of 133.38 and a beta of 1.68.
Tabula Rasa HealthCare (NASDAQ:TRHC) last posted its quarterly earnings data on Wednesday, May 8th. The company reported ($0.14) earnings per share for the quarter, hitting the consensus estimate of ($0.14). Tabula Rasa HealthCare had a negative net margin of 18.15% and a positive return on equity of 4.22%. The firm had revenue of $60.96 million during the quarter, compared to analysts’ expectations of $59.24 million. As a group, sell-side analysts forecast that Tabula Rasa HealthCare Inc will post -0.55 EPS for the current fiscal year.
A number of research analysts have recently issued reports on the stock. Cantor Fitzgerald reiterated a “buy” rating and issued a $99.00 target price on shares of Tabula Rasa HealthCare in a research note on Monday, May 13th. ValuEngine cut shares of Tabula Rasa HealthCare from a “buy” rating to a “hold” rating in a research note on Monday, May 13th. BidaskClub upgraded shares of Tabula Rasa HealthCare from a “sell” rating to a “hold” rating in a research note on Friday, March 22nd. Oppenheimer cut their target price on shares of Tabula Rasa HealthCare from $97.00 to $88.00 and set an “outperform” rating for the company in a research note on Wednesday, March 6th. Finally, Zacks Investment Research cut shares of Tabula Rasa HealthCare from a “hold” rating to a “sell” rating in a research note on Wednesday, May 15th. Five equities research analysts have rated the stock with a hold rating, seven have given a buy rating and one has assigned a strong buy rating to the company’s stock. Tabula Rasa HealthCare presently has an average rating of “Buy” and a consensus target price of $82.12.
TRADEMARK VIOLATION WARNING: This piece was reported by Tech Know Bits and is the property of of Tech Know Bits. If you are accessing this piece on another site, it was copied illegally and republished in violation of United States and international copyright and trademark law. The original version of this piece can be accessed at https://techknowbits.com/2019/06/12/orsula-v-knowlton-sells-8000-shares-of-tabula-rasa-healthcare-inc-trhc-stock.html.
About Tabula Rasa HealthCare
Tabula Rasa HealthCare, Inc operates as a healthcare technology company in the field of medication safety in the United States. The company's proprietary Medication Risk Mitigation Matrix delivers a multi-drug review, which identifies medication-related risks. Its cloud-based software applications include EireneRx, a medication decision-support and e-prescribing platform to access patients' medication-related information; and MedWise that provides medication decision support components for clients seeking to manage their medication risk and improve medication outcomes, and patient relationships by enhancing their existing systems.
Receive News & Ratings for Tabula Rasa HealthCare Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tabula Rasa HealthCare and related companies with MarketBeat.com's FREE daily email newsletter.